Status: Finalised
First registered on:
25/02/2016
Last updated on:
13/01/2021
1. Study identification
EU PAS Register NumberEUPAS12540
Official titleRetrospective Drug Utilisation Study to investigate the routine use of Hydroxyethyl Starch (HES)-containing Infusion Solutions of B. Braun Melsungen AG in Hospitals
Study title acronym
Study typeObservational study
Brief description of the studyThe objective of the Drug Utilisation Study (DUS) is to assess the adherence of hospital physicians to the revised European Product Information (PI) [Summary of Product Characteristics (SmPC); Package Leaflet] for Hydroxyethyl Starch (HES) - containing medicinal products of B. Braun Melsungen AG concerning indication, posology (dosage) and contraindications.
Was this study requested by a regulator?Yes: Sweden
Is the study required by a Risk Management Plan (RMP)?
EU RMP category 1 (imposed as condition of marketing authorisation)
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre nameB. Braun Melsungen AG
Centre locationCarl-Braun-Str. 1, 34212 Melsungen, Germany
Details of (Primary) lead investigator
Title Mr
Last name NA
First name NA
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Multiple centres
In total how many centres are involved in this Study?40
Countries in which this study is being conducted
International study
Belgium
Czech Republic
France
Germany
Italy
Netherlands
Poland
Spain
Sweden
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed14/09/201514/09/2015
Start date of data collection01/03/201601/03/2016
Start date of data analysis28/02/201728/02/2017
Date of interim report, if expected
Date of final study report06/11/201722/09/2017
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesB.Braun Melsungen AG100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Mr
Last name Contact
First name Scientific
Address line 1Carl-Braun-Str. 1
Address line 2
Address line 3
City34212
Postcode
CountryGermany
Phone number (incl. country code)00495661714498
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Mr
Last name Contact
First name Public
Address line 1Carl-Braun-Str. 1
Address line 2
Address line 3
City34212
Postcode
CountryGermany
Phone number (incl. country code)495661714498
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Substance class (ATC Code)B05AA07 (hydroxyethylstarch)
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Preterm newborns
Term newborns (0-27 days)
Infants and toddlers (28 days - 23 months)
Children (2 - 11 years)
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects3000
10. Source of data
Is this study being carried out with an established data source?No
Sources of data
Retrospective non-interventional patient chart study
11. Scope of the study
What is the scope of the study?
Drug utilisation study
Primary scope : Drug utilisation study
12. Main objective(s)
What is the main objective of the study?
The objective of the DUS is to assess the adherence of hospital physicians to the revised European PI for HES-containing medicinal products of B. Braun Melsungen AG concerning indication, posology (dosage) and contraindications.
Are there primary outcomes?Yes
Outcome measure is the adherence to the concerned sections of the revised European PI. Usage of these medicinal products according to indications, posology (dosage), and contraindications as specified in the revised PI of the HES solutions will be assessed.
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Drug utilisation study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
Because of the exploratory character of this study only descriptive statistics will be performed. All parameters will be presented as mean +/- standard deviation for continuous normally distributed variables and median (25th; 75th percentile) for ordinal and continuous non-normal (skewed) variables. Categorical variables will be presented as percentage (and 95 % confidence interval). All analyses will be performed for the overall population as well as for each country separately. All data will be examined for the overall population and subgroups (each site/country separately) specified by indication and contraindications according to the revised PI.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Not submitted
18. Study Results
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
